. . . "13 min-85 min"@en . . "T-cell growth factor"@en . " "@en . "approved"@en . . "IL-2"@en . "Aldesleukin"@en . . . . "Humans and other mammals"@en . . . . . "85898-30-2"@en . "For treatment of adults with metastatic renal cell carcinoma."@en . "Interleukin-2 precursor"@en . "The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules."@en . "0.18 l/kg"@en . . "Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells."@en . . . . . . . . . . "TCGF"@en . . . "Hans-Ake Fabricius, Roland Stahn, \"Serum-free and mitogen-free T-cell growth factor and process for making same.\" U.S. Patent US4464355, issued May, 1971."@en . . . . . "Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125."@en .